A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype

Article Abstract:

A European multicenter study of phenylalanine hydroxylase deficiency has led to a general system for prediction of metabolic phenotype based on genotype and to classification of 105 mutations. Mild hyperphenylalaninemia (MHP) and phenylketonuria (PKU) are allelic disorders caused by mutations in the gene coding for phenylalanine hydroxylase (PAH). Both mutations were found in 686 patients in seven locations in Europe. Based on the phenotypic characteristics of 297 functionally hemizygous patients, 105 of the mutations were assigned to one of four arbitrary phenotype categories. Data show that the PAH-mutation genotype is the primary determinant of metabolic phenotype in most PAH-deficiency patients. The disorder is autosomal recessive.

Denmark, Germany, France, Belgium, Europe, Phenylketonuria, Genetic disorders, Disease susceptibility, Metabolic diseases, Phenylalanine

---

High incidence of later-onset fabry disease revealed by newborn screening

Article Abstract:

Newborn screening by assaying the alpha-Gal A activity in blood spots from 37,104 consecutive Italian male neonates to determine the disease incidence is undertaken. Molecular modeling and in vitro overexpression of the missense mutations demonstrates structures and residual activities, which were rescued/enhanced by an alpha-Gal A-specific pharmalogic chaperone, consistent with mutations that cause the later-onset phenotype.

Analysis, Diagnosis, Gene mutations, Gene mutation, Infants (Newborn), Newborn infants, Haplotypes, Fabry's disease, Toxicity testing, In vitro tests, Clinical report

---

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations

Article Abstract:

Several studies on the Ashkenazi (AJ) and Sephardi Jewish (SJ) patients are conducted to discuss the allele sensitivities and resistance frequencies of two warfarin pharmacogenetics, CYP2C9 and VKORC1.

Jews, Usage, Warfarin, Pharmacogenetics, Pharmacogenomics

Similar abstracts:

• Abstracts: The pattern of gene amplification is determined by the chromosomal location of hairpin-capped breaks. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
• Abstracts: Glycosylation in cellular mechanisms of health and disease. Identification of two proteins required for conjunction and regular segregation of achiasmate homologs in Drosophila male meiosis
• Abstracts: Comparison of methods of extracting Salmonella enterica serovar Enteritidis DNA from environmental substrates and quantification of organisms by using a general internal procedural control
• Abstracts: Heterologous expression of Arabidopsis UDP-glucosyltransferases in Saccharomyces cerevisiae for production of zearalenone-4-O-glucoside
• Abstracts: Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.